Replies to post #2360 on BioCurex, Inc.(fka BOCX)

[oraclewizard77]

Thanks for the update on what's happening with BOCX. I previously made a 100% profitable trade here, but have been out since the stock was on the pinks. I have decided to buy 10,000 shares today and wait for us to get back on otc or AMEX.

For those of you who want to get into another pink trying to get onto the otc, take a look at GFCI and its spinoff CTBG. If you buy GFCI you will eventually get dividends in CTBG. Anyway, they recently hired a CFO, and investors who talked to the CEO have been informed that audits are taking right now to release financials for the very 1st time for CTBG to prepare the company to be transfered to the otc. Anyway, I own alot of GFCI which is trading at 20 cents per share and a little of CTBG which is trading at 27 cents per share. If you are able to get in before financials are released, you will make some real good money. If you want a safer bet, just put it on your watch list, and the day they release financials, buy some shares since you will still have time before they move to the otc.

[Kag]

It would be difficult to pinpoint the underlying reason why investors sold into the Abbott deal announcement almost a year ago. It is always good investment strategy to take profits when it is available. It is my opinion that the stockprice of BOCX is set to do a little soaring with the successful completion of the first milestone which could be announced at any time. That will be Abbott's successful completion of its feasibility review. That announcement will tell Wall Street that Abbott is going to market a RECAF, blood sample, early detection, cancer screening test with a very high sensitivity on its Architect analyzers. Abbott has worldwide rights to market the test. Abbott also has the rights to sublicense the test (with royalties going to BioCurex) for use on other companies rapid test analyzers. Biocurex is also set to recieve minimum royalties commencing with the year ending December 31, 2007. Investors love biotech's with a revenue stream. This stock has the potential to put big smiles on the faces of its investors. What is lacking right now is the announcement of the completion of the first milestone. kag